---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-164550"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2024-06-20T23:59:59+00:00"
generated_at: "2026-06-01T03:38:21.491618+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Director Horobin resigns; shareholders approve plan amendment to include pre-funded warrants in evergreen

## Summary
- Director Joanna Horobin resigned from board and all committees on June 18, 2024; resignation not due to any disagreement.
- Jeffrey Albers appointed to Audit Committee; committee now consists of Ridloff, Esposito, Albers.
- Shareholders approved Amendment No. 1 to 2020 Stock Option Plan: 'Outstanding Shares' includes pre-funded warrants for annual evergreen increase.
- Shareholders elected Class I directors (Esposito, Hrustanovic, Sandor) and ratified Ernst & Young as independent auditor for FY2024.

## SEC filing metadata
- accession: 0001193125-24-164550
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2024-06-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312524164550/0001193125-24-164550-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312524164550/d841500d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-164550
- JSON: https://secwatch.observer/filing/0001193125-24-164550.json
- Plain text: https://secwatch.observer/filing/0001193125-24-164550.txt

## Key facts
- Executive change
  Joanna Horobin resigned as Director at Kymera Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On June 18, 2024, Joanna Horobin, M.B., Ch.B. a member of the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) and the Audit Committee of the Board (the “Audit Committee”) and Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), notified the Company of her resignation from the Board and all committees thereof, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815442/000119312524164550/0001193125-24-164550-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.